Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast

European Journal of Cancer

Volumn 39, Issue 5, 2003, Pages 622-630

  Provenzano, E ^a,b   Hopper, J L ^a   Giles, G G ^c   Marr, G ^c   Venter, D J ^a,d   Armes, J E ^a,b,e,f  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c CANCER EPIDEMIOLOGY CENTRE   (Australia)

^d MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^e MELBOURNE PATHOLOGY   (Australia)

^f ROYAL WOMEN'S HOSPITAL   (Australia)

Author keywords

Bcl 2; Breast cancer; Ductal carcinoma in situ; ERBB2; Oestrogen receptor

Indexed keywords

ANDROGEN RECEPTOR; BIOLOGICAL MARKER; CATHEPSIN D; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; PROTEIN PS2; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; BREAST CARCINOMA; BREAST DUCT; CANCER GRADING; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CARCINOMA IN SITU; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADULT; AGED; BREAST TUMOR; CHEMISTRY; FLUORESCENCE IN SITU HYBRIDIZATION; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PREDICTION AND FORECASTING; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 0242380840     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00666-4     Document Type: Article

References (34)

1. Tavassoli F.A. Ductal carcinoma in situ. introduction of the concept of ductal intraepithelial neoplasia Mod. Pathol. 11:1998;140-154.
2. Ernster V.L., Barclay J., Kerlikowske K., Grady D., Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast [see comments]. Jama. 275:1996;913-918.
3. Boyages J., Delaney G., Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ. a meta-analysis Cancer. 85:1999;616-628.
4. Harris E.E., Solin L.J. The diagnosis and treatment of ductal carcinoma in situ of the breast. Breast J. 6:2000;78-95.
5. Frykberg E.R., Bland K.I. Overview of the biology and management of ductal carcinoma in situ of the breast. Cancer. 74:1994;350-361.
6. Fisher E.R., Dignam J., Tan-Chiu E.et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17. intraductal carcinoma [see comments] Cancer. 86:1999;429-438.
7. Silverstein M.J., Lagios M.D., Craig P.H.et al. A prognostic index for ductal carcinoma in situ of the breast [see comments]. Cancer. 77:1996;2267-2274.
8. Silverstein M.J., Lagios M.D., Groshen S.et al. The influence of margin width on local control of ductal carcinoma in situ of the breast [see comments]. N. Engl. J. Med. 340:1999;1455-1461.
9. Bijker N., Peterse J.L., Duchateau L.et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ. analysis of European Organization for Research and Treatment of Cancer Trial 10853 J. Clin. Oncol. 19:2001;2263-2271.
10. Wells W.A., Carney P.A., Eliassen M.S., Grove M.R., Tosteson A.N. Pathologists' agreement with experts and reproducibility of breast ductal carcinoma-in-situ classification schemes. Am. J. Surg. Pathol. 24:2000;651-659.
11. Douglas-Jones A.G., Morgan J.M., Appleton M.A.et al. Consistency in the observation of features used to classify ductal carcinoma in situ (DCIS) of the breast. J. Clin. Pathol. 53:2000;596-602.
12. Sloane J.P., Amendoeira I., Apostolikas N.et al. Consistency achieved by 23 European pathologists in categorizing ductal carcinoma in situ of the breast using five classifications. European Commission Working Group on Breast Screening Pathology. Hum. Pathol. 29:1998;1056-1062.
13. Perin T., Canzonieri V., Massarut S.et al. Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast. Eur. J. Cancer. 32A:1996;1148-1155.
14. Rajan P.B., Scott D.J., Perry R.H., Griffith C.D. p53 protein expression in ductal carcinoma in situ (DCIS) of the breast. Breast Cancer Res. Treat. 42:1997;283-290.
15. Ringberg A., Anagnostaki L., Anderson H., Idvall I., Ferno M. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. Eur. J. Cancer. 37:2001;1514-1522.
16. Hieken T.J., Farolan M., D'Alessandro S., Velasco J.M. Predicting the biological behavior of ductal carcinoma in situ. an analysis of molecular markers Surgery. 130:2001;593-600.
17. Giles G., Russell I., Reed R., Marr G., Kavanagh A. In situ and small invasive breast cancer register in Victoria, 1988 to 1992. tumour characteristics and patient management ANZ J. Surg. 71:2001;266-270.
18. Rothman Ka.G.S. Case-control studies. Greenland K.G.Ra.S. Modern Epidemiology. 1998;93-114 Lippincott-Raven, Philadelphia.
19. Holland R., Peterse J.L., Millis R.R.et al. Ductal carcinoma in situ. a proposal for a new classification Semin. Diagn. Pathol. 11:1994;167-180.
20. Armes J.E., Trute L., White D.et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers. a population-based study Cancer Res. 59:1999;2011-2017.
21. Solin L.J., Fourquet A., Vicini F.A.et al. Mammographically detected ductal carcinoma in situ of the breast treated with breast-conserving surgery and definitive breast irradiation. long-term outcome and prognostic significance of patient age and margin status Int. J. Radiat. Oncol. Biol. Phys. 50:2001;991-1002.
22. Weng E.Y., Juillard G.J., Parker R.G., Chang H.R., Gornbein J.A. Outcomes and factors impacting local recurrence of ductal carcinoma in situ. Cancer. 88:2000;1643-1649.
23. Vicini F.A., Kestin L.L., Goldstein N.S.et al. Impact of young age on outcome in patients with ductal carcinoma-in-situ treated with breast-conserving therapy. J. Clin. Oncol. 18:2000;296-306.
24. Bobrow L.G., Happerfield L.C., Gregory W.M., Springall R.D., Millis R.R. The classification of ductal carcinoma in situ and its association with biological markers. Semin. Diagn. Pathol. 11:1994;199-207.
25. ilbur D.C., Barrows G.H. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma. an immunohistochemical study Mod. Pathol. 6:1993;114-120.
26. Rudas M., Neumayer R., Gnant M.F., Mittelbock M., Jakesz R., Reiner A. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast [see comments]. Eur. J. Cancer. 33:1997;39-44.
27. Allred D.C., Clark G.M., Molina R.et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum. Pathol. 23:1992;974-979.
28. Barnes D.M., Bartkova J., Camplejohn R.S., Gullick W.J., Smith P.J., Millis R.R. Overexpression of the c-erbB-2 oncoprotein. why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur. J. Cancer. 28:1992;644-648.
29. Gusterson B.A., Machin L.G., Gullick W.J.et al. Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer. Int. J. Cancer. 42:1988;842-845.
30. Quinn C.M., Ostrowski J.L., Harkins L., Rice A.J., Loney D.P. Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins. Histopathology. 33:1998;531-536.
31. Oh Y.L., Choi J.S., Song S.Y.et al. Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ. relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status Pathol. Int. 51:2001;94-99.
32. Mommers E.C., Leonhart A.M., Falix F.et al. Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade. J. Pathol. 194:2001;327-333.
33. Barbareschi M., Caffo O., Doglioni C.et al. p21WAF1 immunohistochemical expression in breast carcinoma. correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival Br. J. Cancer. 74:1996;208-215.
34. McClelland R.A., Gee J.M., O'Sullivan L.et al. p21(WAF1) expression and endocrine response in breast cancer. J. Pathol. 188:1999;126-132.